Azintuxizumab vedotin
Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells[1].
Product Specifications
CAS Number
1826819-58-2
Product Name Alternative
ABBV-838
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs)
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/azintuxizumab-vedotin.html
Purity
98.55
Solubility
H2O
Smiles
[Azintuxizumabvedotin]
Molecular Weight
(146.036 kDa)
References & Citations
[1]Vij R, et al. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clin Cancer Res. 2020 May 15;26 (10) :2308-2317.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680012-500 1x 500 µL
Tyrosinase (T311), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC551037-100 1x 100 µL
CD44 Standard (DF1485), CF555 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740177-100 1x 100 µL
CD50 (ICAM-3) (101-1D2), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details